Filters
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis
Heneghan, M. A., et al. (2022)
EClinicalMedicine
Read Summary ▾
First-of-its-kind evaluation in biopsy-proven AIH: LiverMultiScan’s cT1 increases clinician confidence and influences management by improving disease characterization and early detection of patients in biochemical remission with undetected, active sub-clinical disease at a high risk of relapse, compared to VCTE and serum biomarkers alone.
Pancreas MRI Segmentation Into Head, Body, and Tail Enables Regional Quantitative Analysis of Heterogeneous Disease
Bagur, A., et al. (2022)
Journal of Magnetic Resonance Imaging
Read Summary ▾
A novel MRI segmentation algorithm divides the pancreas into head, body, and tail, enabling regional quantification. It achieved excellent accuracy and reproducibility, supporting assessment of heterogeneous pancreatic disease and revealing subsegment-specific alterations in diabetes.
Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device
Carolan, J. E., et al., (2022)
JMIR Medical Informatics
Read Summary ▾
Opinion piece on regulating Artificial Intelligence (AI) and Machine Learning (ML) in software as a medical device (SaMD): advocates stronger technology literacy, clear evidence standards across the full product lifecycle, and continuous engagement of end-users to demonstrate safety and effectiveness—shifting SaMD oversight to be technology-enabled, evidence-driven, and patient-centred.
Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease
McCrary, J., et al. (2022)
American Journal of Roentgenology
Read Summary ▾
In a population of children and young adults with autoimmune liver disease (AILD), quantitative metrics from LiverMultiScan and MRCP+ were significantly associated with the MAYO and SCOPE risk scores and were independent predictors. These findings support multiparametric MRI using LiverMultiScan and MRCP+ as noninvasive tools for diagnosis risk stratification, and prognosis in AILD.
Associations between MRI T1 mapping, liver stiffness, quantitative MRCP, and laboratory biomarkers in children and young adults with autoimmune liver disease
Mahalingam, N., et al. (2021)
Abdominal Radiology
Read Summary ▾
In paediatric and young adult with autoimmune liver disease AILD, multiparametric MRI (LiverMultiScan) and MRCP+ showed robust associations with laboratory markers. cT1 correlated with markers of liver disease activity, and cT1 IQR appeared less confounded than MRE. MRCP+ biliary metrics discriminated AIH from PSC/ASC, supporting combined imaging for noninvasive stratification and monitoring.
Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease
Harrison, S. A., et al. (2021)
The American Journal of Gastroenterology
Read Summary ▾
cT1 (LiverMultiScan) was significantly reduced after 16 weeks of novel NASH treatment, AXA1125, versus placebo, with twice as many patients achieving a reduction of cT1 ≥ 80 ms, previously linked to improved histopathological outcomes. AXA1125 also reduced liver fat (MRI-PDFF) and improved metabolic and fibro-inflammatory markers (HOMA-IR, ALT, CK18-M65, Pro-C3).
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance
Johnson, K., et al. (2021)
JHEP Reports
Read Summary ▾
In LITMUS, serum miRNA profiling identified elevated miR-193a-5p with worsening fibrosis and higher NAS/SAF scores, replicated in an independent cohort. Findings support circulating miRNAs, especially miR-193a-5p, as noninvasive biomarkers to detect advanced NAFLD without a liver biopsy.
Improved pathology reporting in NAFLD/NASH for clinical trials
Langford, C. R., et al. (2021)
Journal of Clinical Pathology
Read Summary ▾
Synoptic reporting provides a comprehensive and structured format, which results in a complete assessment of liver disease. This opinion piece proposes using synoptic reporting, in place of the existing narrative style, in liver biopsies for NAFLD and NASH clinical trials to improve trial success rates and accelerate drug development.
Comparison of quantitative 3D magnetic resonance cholangiography measurements obtained using three different image acquisition methods
Mahalingam, N., et al. (2021)
Abdominal Radiology
Read Summary ▾
This study compares quantitative biliary measurements obtained using MRCP+ and three different MRCP acquisition methods, showing that MRCP with compressed sensing to reduce acquisition time produced comparable biliary diameter metrics and global duct quantification to clinically indicated MRCP.
Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis
Andersson, A., et al. (2021)
Clinical Gastroenterology and Hepatology
Read Summary ▾
Multicenter, biopsy-paired NAFLD analysis shows MRI PDFF and cT1 accurately identify NASH; cT1 better pinpoints patients at high risk of progression than liver fat alone. The data supports cT1 as a noninvasive biomarker for triage, risk stratification, and trial enrichment.
Repeatability and reproducibility of deep‑learning‑based liver volume and Couinaud segment volume measurement tool
Mojtahed, A., et al. (2021)
Abdominal Radiology
Read Summary ▾
Automated Hepatica delivered accurate, repeatable liver and Couinaud segment volumes, matching expert radiologists while reducing inter-operator variability and measurement time. Standardized, deep-learning outputs support robust pre-surgical planning and comprehensive liver health assessment.
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., et al. (2021)
JHEP Reports
Read Summary ▾
Multistakeholder NAFLD guideline—co-developed by patients, patient representatives, clinicians, and scientists—summarizes current care pathways. The emerging noninvasive tests section highlights multiparametric MRI as a promising tool to identify NASH with fibrosis, referencing Schaapman et al. (2020), which integrated LiverMultiScan cT1 into a clinical risk-assessment algorithm for NAFLD.
Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway
McKay, A., et al. (2021)
Journal of Patient-Reported Outcomes
Read Summary ▾
Automated Hepatica delivered accurate, repeatable liver and Couinaud segment volumes, matching expert radiologists while reducing inter-operator variability and measurement time. Standardized, deep-learning outputs support robust pre-surgical planning and comprehensive liver health assessment.
Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease
Janowski, K., et al. (2021)
Scientific Reports
Read Summary ▾
Paediatric AILD cohort with AIH and ASC underwent LiverMultiScan, MRCP+, biopsy, and blood-based liver function tests. Quantitative MRCP+ biliary metrics discriminated AIH from ASC, supporting noninvasive subtype stratification. Although cT1 did not differ between subtypes, LiverMultiScan provided parenchymal characterization and longitudinal monitoring, complementing MRCP+ for comprehensive assessment.